| |
NAC group(n = 45)
|
Placebo group(n = 45b)
|
P value
|
|---|
|
Primary end-point
| | | |
|
Incidence of CIN, n(%)
|
5(11.1%)
|
6(14.3%)
|
0.656
|
|
Secondary end-points
| | | |
|
Change in serum creatinine, mg/dL
|
-0.016 ± 0.363
|
-0.018 ± 0.467
|
0.975
|
|
Change in serum urea nitrogen, mg/dL
|
-1.73 ± 24.03
|
-3.71 ± 24.26
|
0.703
|
|
Change in creatinine clearance, mL/min
|
2.86 ± 8.84
|
3.78 ± 10.87
|
0.676
|
-
a All plus-minus values are mean ± SD. CIN, contrast-induced nephropathy.
-
bWhile 45 patients were enrolled in each group, serum creatinine and urea nitrogen measurements were not available for 3 placebo patients who were discharged immediately after coronary angiography and did not return for subsequent blood sampling (comparison, 45 NAC patients vs. 42 placebo patients).
